Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease
โ Scribed by Timothy L. Zisman; Russell D. Cohen
- Publisher
- Springer
- Year
- 2007
- Tongue
- English
- Weight
- 134 KB
- Volume
- 10
- Category
- Article
- ISSN
- 1092-8472
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Inflammatory bowel disease (IBD), which encompasses Crohn's disease (CD) and ulcerative colitis (UC), are chronic and debilitating conditions with unpredictable courses and complicated treatment. Pediatric IBD carries implications that extend beyond the health of the gastrointestinal tract. When the
## Background: The aim was to assess quality of life (QOL) and psychological functioning in inflammatory bowel disease (IBD) as related to patterns of disease activity over time. Methods: Study participants were 388 recently diagnosed individuals from the population-based Manitoba IBD Cohort Stud
## Background: Approximately 20%-25% of all inflammatory bowel disease (ibd) cases have an onset in childhood or adolescence. beyond disease severity, little is known regarding determinants of health-related quality of life (hrqol) in this population. this study aimed to identify behavioral correla